{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T08:41:18Z","timestamp":1769157678836,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T00:00:00Z","timestamp":1571097600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T00:00:00Z","timestamp":1571097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1137180"],"award-info":[{"award-number":["OPP1137180"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In settings such as China, where universal implementation of directly observed therapy (DOT) is not feasible, innovative approaches are needed to support patient adherence to TB treatment. The electronic medication monitor (EMM) is one of the digital technologies recommended by the World Health Organization (WHO), but evidence from implementation studies remains sparse. In this study, we evaluated acceptance of the EMM among health care workers and patients while implementing the device for differential TB patient management at the community level.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Zhenjiang City in Jiangsu Province was purposively selected for the study. All participating patients were allowed to select their preferred management approach. If patients declined to use the EMM, DOT was offered. The EMM was designed to hold 1 month of anti-TB drugs for once-daily dosing of fixed-dose combination (FDC) tablets. Patient EMM records were monitored monthly by a physician; if 20 to 50% of doses were missed twice, or more than 50% of doses were missed once, the patient was switched to DOT. The four physicians and five nurses involved in the study at four designated hospitals were surveyed using a structured questionnaire to assess their acceptance of the EMM.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>From October 2017 through January 2018, 316 pulmonary TB patients were notified in the TB information management system, and 231 (73.1%) met the study enrollment criteria. Although 186 patients (80.5%) initially consented to use the EMM, 17 later refused to use it. Among the 169 patients who used the EMM, 15 (8.9%) were switched to DOT due to poor adherence, and the other 154 completed the treatment course. The median adherence rate was 99.3%. Surveyed health care workers from designated hospitals found the EMM acceptable, although eight of nine felt use of the device moderately increased their workload. However, the EMM program significantly reduced the workload of community physicians by reducing patient visits by 87.9%.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study demonstrated the acceptability of using an indigenously developed EMM for differential management of TB patients at the community level. However, more operational research should be conducted before introducing and scaling the technology throughout China.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-019-4521-2","type":"journal-article","created":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T12:47:42Z","timestamp":1571143662000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Using electronic medication monitoring to guide differential management of tuberculosis patients at the community level in China"],"prefix":"10.1186","volume":"19","author":[{"given":"Ni","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miaomiao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amelia","family":"Kinter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8620-3869","authenticated-orcid":false,"given":"Fei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,15]]},"reference":[{"key":"4521_CR1","unstructured":"Global tuberculosis report 2018. Geneva: World Health Organization; 2018. Available from: \n                    https:\/\/www.who.int\/tb\/publications\/global_report\/en\/\n                    \n                  .\u00a0Accessed 8 Oct 2019."},{"issue":"1","key":"4521_CR2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.4103\/2141-9248.109507","volume":"3","author":"P Kulkarni","year":"2013","unstructured":"Kulkarni P, Akarte S, Mankeshwar R, Bhawalkar J, Banerjee A, Kulkarni A. Non-adherence of new pulmonary tuberculosis patients to anti-tuberculosis treatment. Ann Med Health Sci Res. 2013;3(1):67\u201374.","journal-title":"Ann Med Health Sci Res"},{"key":"4521_CR3","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1186\/s13104-015-1452-x","volume":"8","author":"G Tesfahuneygn","year":"2015","unstructured":"Tesfahuneygn G, Medhin G, Legesse M. Adherence to anti-tuberculosis treatment and treatment outcomes among tuberculosis patients in Alamata District, northeast Ethiopia. BMC Res Notes. 2015;8:503.","journal-title":"BMC Res Notes"},{"key":"4521_CR4","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/1472-6963-9-169","volume":"9","author":"W Xu","year":"2009","unstructured":"Xu W, Lu W, Zhou Y, Zhu L, Shen H, Wang J. Adherence to anti-tuberculosis treatment among pulmonary tuberculosis patients: a qualitative and quantitative study. BMC Health Serv Res. 2009;9:169.","journal-title":"BMC Health Serv Res"},{"key":"4521_CR5","unstructured":"Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003. Available from: \n                    http:\/\/www.who.int\/chp\/knowledge\/publications\/adherence_report\/en\/\n                    \n                  . Accessed 8 Oct 2019."},{"issue":"11","key":"4521_CR6","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.5588\/ijtld.12.0080","volume":"16","author":"WL Hou","year":"2012","unstructured":"Hou WL, Song FJ, Zhang NX, Dong XX, Cao SY, Yin XX, et al. Implementation and community involvement in DOTS strategy: a systematic review of studies in China. Int J Tuberc Lung Dis. 2012;16(11):1433\u201340.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"9","key":"4521_CR7","doi-asserted-by":"publisher","first-page":"e1001876","DOI":"10.1371\/journal.pmed.1001876","volume":"12","author":"X Liu","year":"2015","unstructured":"Liu X, Lewis JJ, Zhang H, Lu W, Zhang S, Zheng G, et al. Effectiveness of electronic reminders to improve medication adherence in tuberculosis patients: a cluster-randomised trial. PLoS Med. 2015;12(9):e1001876.","journal-title":"PLoS Med"},{"key":"4521_CR8","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1016\/S0140-6736(13)62639-2","volume":"383","author":"L Wang","year":"2014","unstructured":"Wang L, Zhang H, Ruan Y, Chin DP, Xia Y, Cheng S, et al. Tuberculosis prevalence in China, 1990\u20132010; a longitudinal analysis of national survey data. Lancet. 2014;383:2057\u201364.","journal-title":"Lancet"},{"key":"4521_CR9","unstructured":"Digital health for the end TB strategy: an agenda for action. Geneva: World Health Organization; 2015. Available from: \n                    http:\/\/www.who.int\/tb\/publications\/digitalhealth-TB-agenda\/en\/\n                    \n                  .\u00a0Accessed 8 Oct 2019."},{"key":"4521_CR10","unstructured":"Guidelines for the treatment of drug-susceptible tuberculosis and patient care (2017 update). Geneva: World Health Organization; 2017. Available from: \n                    https:\/\/www.who.int\/tb\/publications\/2017\/dstb_guidance_2017\/en\/\n                    \n                  .\u00a0Accessed 8 Oct 2019."},{"key":"4521_CR11","unstructured":"Handbook for the use of digital technologies to support tuberculosis medication adherence. Geneva: World Health Organization; 2017. Available from: \n                    https:\/\/www.who.int\/tb\/publications\/2018\/TB_medication_adherence_handbook_2018\/en\/\n                    \n                  .\u00a0Accessed 8 Oct 2019."},{"key":"4521_CR12","doi-asserted-by":"publisher","unstructured":"Liu X, Blaschke T, Thomas B, De Geest S, Jiang S, Gao Y, et al. Usability of a medication event reminder monitor system (MERM) by providers and patients to improve adherence in the management of tuberculosis. Int J Environ Res Public Health. 2017;14(10). \n                    https:\/\/doi.org\/10.3390\/ijerph14101115\n                    \n                  .","DOI":"10.3390\/ijerph14101115"},{"key":"4521_CR13","unstructured":"General Office of the State Council. China national 13th five year plan on TB control (2016\u20132020). Available from: \n                    http:\/\/www.gov.cn\/zhengce\/content\/2017-02\/16\/content_5168491.htm.Chinese\n                    \n                  .\u00a0Accessed 8 Oct 2019."},{"key":"4521_CR14","doi-asserted-by":"publisher","unstructured":"Ngwatu BK, Nsengiyumva NP, Oxlade O, Mappin-Kasirer B, Nguyen NL, Jaramillo E, et al. The impact of digital health technologies on tuberculosis treatment: a systematic review. Eur Respir J. 2018;51(1). \n                    https:\/\/doi.org\/10.1183\/13993003.01596-2017\n                    \n                  .","DOI":"10.1183\/13993003.01596-2017"},{"key":"4521_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1183\/13993003.00424-2016","volume":"48","author":"D Falzon","year":"2016","unstructured":"Falzon D, Timimi H, Kurosinski P, Migliori GB, Van Gemert W, Denkinger C, et al. Digital health for the end TB strategy: developing priority products and making them work. Eur Respir J. 2016;48:29\u201345.","journal-title":"Eur Respir J"},{"key":"4521_CR16","unstructured":"Statistical yearbook of Zhenjiang 2018. Available from: \n                    http:\/\/tjj.zhenjiang.gov.cn\/tjzl\/tjnj\/201811\/t20181105_2094869.htm.Chinese\n                    \n                  .\u00a0Accessed 8 Oct 2019."},{"issue":"10","key":"4521_CR17","doi-asserted-by":"publisher","first-page":"e0164172","DOI":"10.1371\/journal.pone.0164172","volume":"11","author":"EO Masini","year":"2016","unstructured":"Masini EO, Mansour O, Speer CE, Addona V, Hanson CL, Sitienei JK, et al. Using survival analysis to identify risk factors for treatment interruption among new and retreatment tuberculosis patients in Kenya. PLoS One. 2016;11(10):e0164172.","journal-title":"PLoS One"},{"key":"4521_CR18","first-page":"4850324","volume":"2017","author":"S Krasniqi","year":"2017","unstructured":"Krasniqi S, Jakupi A, Daci A. Tuberculosis treatment adherence of patients in Kosovo. Tuberc Res Treat. 2017;2017:4850324.","journal-title":"Tuberc Res Treat"},{"issue":"6","key":"4521_CR19","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s40265-013-0041-3","volume":"73","author":"J Demonceau","year":"2013","unstructured":"Demonceau J, Ruppar T, Kristanto P, Hughes DA, Fargher E, Kardas P, et al. Identification and assessment of adherence-enhancing interventions in studies assessing medication adherence through electronically compiled drug dosing histories: a systematic literature review and meta-analysis. Drugs. 2013;73(6):545\u201362.","journal-title":"Drugs"},{"issue":"12","key":"4521_CR20","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1001\/jama.2014.10059","volume":"312","author":"KD Checchi","year":"2014","unstructured":"Checchi KD, Huybrechts KF, Avorn J, Kesselheim AS. Electronic medication packaging devices and medication adherence: a systematic review. JAMA. 2014;312(12):1237\u201347.","journal-title":"JAMA"},{"issue":"5","key":"4521_CR21","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1586\/17512433.2014.940896","volume":"7","author":"B Vrijens","year":"2014","unstructured":"Vrijens B, Urquhart J, White D. Electronically monitored dosing histories can be used to develop a medication-taking habit and manage patient adherence. Expert Rev Clin Pharmacol. 2014;7(5):633\u201344.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"7","key":"4521_CR22","first-page":"419","volume":"34","author":"S Huan","year":"2012","unstructured":"Huan S, Chen R, Liu X, Ou X, Jiang S, Zhao Y, et al. Operational feasibility of medication monitors in monitoring treatment adherence among TB patients. Chinese J Antituberc. 2012;34(7):419\u201324 Chinese.","journal-title":"Chinese J Antituberc"},{"issue":"7","key":"4521_CR23","doi-asserted-by":"publisher","first-page":"855","DOI":"10.5588\/ijtld.10.0486","volume":"15","author":"T Moulding","year":"2011","unstructured":"Moulding T. A neglected research approach to prevent acquired drug resistance when treating new tuberculosis patients. Int J Tuberc Lung Dis. 2011;15(7):855\u201361.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"4","key":"4521_CR24","first-page":"313","volume":"6","author":"TS Moulding","year":"2002","unstructured":"Moulding TS, Caymittes M. Managing medication compliance of tuberculosis patients in Haiti with medication monitors. Int J Tuberc Lung Dis. 2002;6(4):313\u20139.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"11","key":"4521_CR25","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1038\/s41591-018-0224-2","volume":"24","author":"M Imperial","year":"2018","unstructured":"Imperial M, Nahid P, Phillips P, Davies G, Fielding K, Hanna D, et al. A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. Nat Med. 2018;24(11):1708\u201315.","journal-title":"Nat Med"},{"issue":"7","key":"4521_CR26","doi-asserted-by":"publisher","first-page":"e1002595","DOI":"10.1371\/journal.pmed.1002595","volume":"15","author":"N Alipanah","year":"2018","unstructured":"Alipanah N, Jarlsberg L, Miller C, Linh NN, Falzon D, Jaramillo E, Nahid P. Adherence interventions and outcomes of tuberculosis treatment: a systematic review and meta-analysis of trials and observational studies. PLoS Med. 2018;15(7):e1002595.","journal-title":"PLoS Med"},{"issue":"1","key":"4521_CR27","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1186\/s13063-018-2650-3","volume":"19","author":"JJ Lewis","year":"2018","unstructured":"Lewis JJ, Liu X, Zhang Z, Thomas BV, Vassall A, Sweeney S, et al. Evaluation of a medication monitor-based treatment strategy for drug-sensitive tuberculosis patients in China: study protocol for a cluster randomized controlled trial. Trials. 2018;19(1):398.","journal-title":"Trials"},{"issue":"1","key":"4521_CR28","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1089\/tmj.2011.0143","volume":"18","author":"S Broomhead","year":"2012","unstructured":"Broomhead S, Mars M. Retrospective return on investment analysis of an electronic treatment adherence device piloted in the northern Cape Province. Telemed J E Health. 2012;18(1):24\u201331.","journal-title":"Telemed J E Health"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4521-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-019-4521-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4521-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T23:08:06Z","timestamp":1602630486000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-019-4521-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,15]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["4521"],"URL":"https:\/\/doi.org\/10.1186\/s12879-019-4521-2","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,15]]},"assertion":[{"value":"6 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the ethics committee of the Chinese Center for Disease Control and Prevention (201626). Physicians introduced the advantages of the EMM to all participating patients, allowing the patients to select their preferred management approach, the verbal consent of using EMM was obtained at the BMU. If the patients consent to use EMM, they were required to sign a consent form later by the community physicians at the first home visit. If the patients declined to use the EMM, DOT was offered.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"844"}}